Regina Esinam Abotsi is a L'Oréal-UNESCO For Women in Science and Organisation of Women in Science for the Developing World PhD Fellow at the Department of Molecular and Cell Biology, University of Cape Town. Her previous research on the molecular mechanisms underlying an emerging fluoroquinolone resistance in Haemophilus species isolated from private sector patients in Durban earned her a master of Pharmaceutical Microbiology degree from the University of KwaZulu-Natal, South Africa in 2016. During her masters she participated in two desktop analyses on antimicrobial resistance in the WHO AFRO and EMRO regions leading to a publication (Perspectives Antimicrobial resistance in the WHO African region: current status and roadmap for action) and a report. She obtained her Bachelor of Pharmacy degree from the Kwame Nkrumah University of Science and Technology, Ghana in 2012. Ms Abotsi is a registered pharmacist in Ghana and also an Assistant Lecturer at the University of Health and Allied Science, Ghana. Her current research focuses on the effect of long-term azithromycin therapy on the respiratory microbiota of African children with HIV-associated chronic lung disease and the skin microbiota of children with atopic dermatitis. Her other research interests are molecular epidemiology of antibiotic resistance, antibiotic stewardship policy formulation and implementation by developing countries.

Pr. Ouissal Aissaoui, MD, Anesthesiology and intensive care medicine specialist. She worked in COVID-19 dedicated ICU during 2020. She is currently an Assistant Professor of Pediatric anesthesiology and intensive care medicine at Children's University hospital of Casablanca. She is conducting research on pediatric sepsis and pediatric acute kidney injury.

Mark Alderson, PhD, MBA, Center for Vaccine Innovation and Access, PATH (Seattle, USA) Dr. Alderson is the Bacterial Vaccine Initiative Leader with PATH’s Center for Vaccine Innovation and Access, playing a lead role in the Pneumococcal Vaccine Project (PVP), Group B Streptococcal (GBS) Vaccine Project and Meningococcal Vaccine Project, Polyvalent (MVPP). These projects seek to accelerate the development and licensure of promising pneumococcal, GBS and meningococcal vaccines and ensure their availability and use in developing countries. Dr. Alderson led the PATH team that worked in close collaboration with the Serum Institute of India to develop, license and WHO prequalify the 10-valent pneumococcal conjugate vaccine, PNEUMOSIL, in 2019. Dr. Alderson has more than 30 years of experience in medical research, biotechnology, pharmaceuticals and vaccine development. He joined PATH in August, 2006, serving initially as PVP Scientific Director until his appointment as PVP Director in July, 2007. He was appointed MVPP director in 2012 and GBS Vaccine Project Director in 2016. Prior to joining PATH, Dr. Alderson was Director of Immunology at GlaxoSmithKline Biologicals, Seattle, where he led preclinical work on synthetic adjuvants for a variety of vaccine targets. Prior to GSK, he was Senior Director of Immunology at Corixa Corporation where he was responsible for the preclinical discovery and evaluation of adjuvants and vaccines for tuberculosis, Chlamydia and HSV. Dr. Alderson has published over 100 manuscripts in peer reviewed journals. He served as an Affiliate Associate Professor, Department of Pathobiology at the University of Washington from 2002 until 2006. Dr. Alderson earned his PhD in immunology at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia and his MBA at Seattle University, USA.

Dr Tinsae Alemayehu is a pediatric infectious diseases specialist, medical educator and researcher based in Ethiopia. He is affiliated to the American medical center and also as an adjunct assistant professor to the St. Paul's hospital millennium medical college, Addis Ababa. He is also the current vice president of the African society of pediatric infectious diseases (AfSPID). Dr Tinsae has published 35 articles in peer-reviewed journals. His research interests are antimicrobial resistance and stewardship practices relevant to childhood infections in low resource settings. He has recently co-authored the pan-African antimicrobial treatment guidelines for common infections and syndromes in pediatric patients prepared by the Africa CDC and Center for Disease Dynamics, Economics and Policy. He co-directs the Addis Ababa-McGill University partnership for infectious diseases - a research group which thrives to promote research and training in Infectious and Tropical Diseases and in particular, antimicrobial stewardship. He's also member of the editorial team of the PLoS Global Health journal. Dr Tinsae also has experience in national outbreak control efforts in his home country including authoring national management guidelines for syndromes like pediatric COVID, Chikungunya, Dengue, viral hepatitis etc.

Dr. Álvarez is a physician from the National Polytechnic Institute (Mexico), Master in Public Health from the National Institute of Public Health (Mexico), and Doctor in Epidemiology from the University of Michigan, USA. He is Professor-Researcher of the Department of Medicine and Health Sciences, University of Sonora. In addition, he has worked for 28 years as an epidemiologist in the Ministry of Health of the State of Sonora. He is National Researcher Level 2 of the National Council of Science and Technology (CONACYT).

Medico (UBA), DTM&H (RCP), MRCPCH (UK) Contact: g.amenosbarraza@nhs.net Languages: English, Spanish

MSc Microbiology student at Umm Al-Qura University

Dra. Celia M.Alpuche Aranda. She is a Pediatric Infectious Diseases physician with a PhD in Science-Microbiology and a Post-Doctoral fellowship at the Infectious Diseases Unit-Massachusetts Dra. Celia M.Alpuche Aranda. In Mexico, she was an attending physician and Chief Department of Enteropathogens Laboratory at the Hospital Infantil de México Federico Gomez, Mexico; coordinator of the Infectious diseases and Clinical Microbiology laboratory-Experimental Medicine Department-Medical School-National University of Mexico, Director of the Epidemiological Diagnosis and Reference Laboratory of the MOH-Mexico (key element in 2009 influenza pandemic response), mentored undergraduate, master's and PhD students and she has published more than 100 peer review manuscripts. She is member of the National System of Investigators in México (SNI III). Currently, she is Director of the Research Center for Infectious Diseases at the National Institute of Public Health in Mexico. She participates in technical and advisory groups at the national and international level (PAHO/WHO, United Nations, etc. Currently she is Coordinator of the NITAG, and the specific for COVID-19, she participate as a member of the WHO, SAGE Working group on COVID-19 vaccines.